Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function

Abstract

Anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy is effective and well-tolerated for refractory or relapsed multiple myeloma (RRMM). The purpose of the present study was to analyze efficacy in RRMM patients with renal impairment treated by anti-BCMA CAR-T cell therapy. A total of 59 RRMM patients were selected, and divided into impaired renal function (IRF) group [baseline estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m² (n=18)] and normal renal function (NRF) group (baseline eGFR ≥ 90 mL/min/1.73 m², n=41). For patients with IRF, eGFR at the 6th month post-CAR-T cells infusion was significantly higher than the baseline (P<0.05). The multivariate analysis showed that light chain type and beta-2 micro-globulin (beta-2M) were associated factors with the decrease of serum creatinine. Median progression-free survival (PFS) in the NRF group and IRF group was 266 days and 181 days respectively. Overall survival (OS) in the NRF group and IRF group was 877 days and 238 days respectively. There was no significant difference in the objective response rate (ORR) between the IRF group and the NRF group. It is suggested that CAR-T cells therapy could improve the renal function during the treatment of RRMM. The renal function could be more significantly improved in RRMM patients with light chain type than with other types.

Keywords

relapsed or refractory multiple myeloma / chimeric antigen receptor T-cell therapy / impaired renal function / B cell maturation antigen

References

[1] ClarkAD, ShettyA, SoutarR. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev, 1999, 13(2): 79-90

[2] NasrSH, ValeriAM, SethiS, et al.. Clinicopathologic Correlations in Multiple Myeloma: A Case Series of 190 Patients With Kidney Biopsies. Am J Kidney Dis, 2012, 59(6): 786-794

[3] CohenG, HorlWH. Free Immunoglobulin Light Chains as a Risk Factor in Renal and Extrarenal Complications. Semin Dialysis, 2009, 22(4): 369-372

[4] DimopoulosMA, KastritisE, RosinolL, et al.. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia, 2008, 22(8): 1485-1493

[5] Eleutherakis-PapaiakovouV, BamiasA, GikaD, et al.. Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance. Leuk Lymphoma, 2007, 48(2): 337-341

[6] KhanR, ApewokinS, GrazziuttiM, et al.. Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. Leukemia, 2015, 29(5): 1195-1201

[7] LiuDL. CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. J Hematol Oncol, 2019, 12(1): 113

[8] MohyuddinGR, RooneyA, BalmacedaN, et al.. Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood Adv, 2021, 5(4): 1097-1101

[9] YuB, JiangTB, LiuDL. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol, 2020, 13(1): 125

[10] RajeN, BerdejaJ, LinY, et al.. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med, 2019, 380(18): 1726-1737

[11] HaoSG, JinJ, YuK, et al.. CT053, Anti-BCMA CAR T-cell therapy for Relapsed/Refractory Multiple Myeloma: Proof of Concept results from a Phase I Study. Clin Lymphoma Myeloma Leuk, 2019, 19(10): E54-E55

[12] LiC, CaoW, QueY, et al.. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med, 2021, 11(3): e346

[13] WangD, WangJ, HuG, et al.. A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2021, 137(21): 2890-2901

[14] RajkumarSV, DimopoulosMA, PalumboA, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol, 2014, 15(12): E538-E548

[15] WalkJC, AyatiBP, HolsteinSA. Modeling the Effects of Multiple Myeloma on Kidney Function. Sci Rep-Uk, 2019, 9(1): 1726

[16] WeiselKC, DimopoulosMA, MoreauP, et al.. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low — dose dexamethasone versus high — dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica, 2016, 101(7): 872-878

[17] ChenX, WangZQ, ZhuGY, et al.. The references level of cadmium intake for renal dysfunction in a Chinese population. Sci Rep-Uk, 2018, 8(1): 9011

[18] LiuBX, LuF, LinJ, et al.. Correlations of serum beta 2-microglobulin level with disease activity and renal involvement in patients with systemic lupus erythematosus. J Lab Med, 2021, 45(1): 13-18

[19] MiyataT, JadoulM, KurokawaK, et al.. beta-2 microglobulin in renal disease. J Am Soc Nephrol, 1998, 9(9): 1723-1735

[20] RainoneF, MerlinoL, RitchieJP, et al.. Multiple Myeloma with Acute Kidney Injury Is the Expression of a More Aggressive Disease. A 10 Year Single Renal Center Experience. Nephrol Dial Transpl, 2013, 28: 344-344

[21] DimopoulosMA, TerposE, Chanan-KhanA, et al.. Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. J Clin Oncol, 2010, 28(33): 4976-4984

[22] DimopoulosMA, LeleuX, MoreauP, et al.. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia, 2021, 35(2): 562-572

[23] ZhouDB, YuL, DuX, et al.. Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment. Int J Hemato, 2015, 101(6): 569-577

[24] DimopoulosM, WeiselK, van de DonkN, et al.. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. J Clin Oncol, 2018, 36(20): 2035-2043

[25] WitteHM, BonordenB, RieckeA, et al.. The Glasgow Prognostic Score at Diagnosis Is a Predictor of Clinical Outcome in Patients with Multiple Myeloma Undergoing Autologous Haematopoietic Stem Cell Transplantation. Cancers, 2020, 12(4): 921